This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Exane BNP Paribas analyst Kevin Grundy initiated coverage on Constellation Brands, Inc. STZ with a Neutral rating and announced a price target of $261. Constellation Brands shares closed at $239.66 on Friday. See how other analysts view this stock.
TD Cowen analyst Joseph Thome initiated coverage on Viridian Therapeutics, Inc. VRDN with a Buy rating. Viridian Therapeutics shares closed at $20.20 on Friday. See how other analysts view this stock.
Canaccord Genuity analyst Edward Nash initiated coverage on Apogee Therapeutics, Inc. APGE with a Buy rating and announced a price target of $89. Apogee Therapeutics shares closed at $43.46 on Friday. See how other analysts view this stock.
UBS analyst Timothy Arcuri initiated coverage on Arm Holdings plc ARM with a Buy rating and announced a price target of $160. ARM shares closed at $135.99 on Friday. See how other analysts view this stock.
HC Wainwright & Co. analyst Mitchell Kapoor initiated coverage on Sarepta Therapeutics, Inc. SRPT with a Sell rating and announced a price target of $80. Sarepta Therapeutics shares closed at $114.23 on Friday. See how other analysts view this stock.